Drug intelligence / Profile preview

Finamine

Development stage: Phase 1
Lead developer: Yiling Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Finamine is an investigational drug developed by Yiling Pharmaceutical Inc. It is administered orally as tablets and is currently undergoing a randomized, double-blind, placebo-controlled, single-dose, dose-escalation study in Chinese healthy adult subjects. The primary objectives of this study are to assess its tolerability, safety, and pharmacokinetic characteristics, and to establish a basis for dose setting in future clinical studies. The specific mechanism of action and primary indication for Finamine are not disclosed in the provided context.

Other names: Finamine tablets

Beyond the preview

Go deeper on Finamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Finamine.

Explore the full profile